CN106344564A - Application of indole-3-carbinol and diindolylmethane and derivatives thereof in preparation of medicines for treating hair follicle keratosis - Google Patents
Application of indole-3-carbinol and diindolylmethane and derivatives thereof in preparation of medicines for treating hair follicle keratosis Download PDFInfo
- Publication number
- CN106344564A CN106344564A CN201610653804.0A CN201610653804A CN106344564A CN 106344564 A CN106344564 A CN 106344564A CN 201610653804 A CN201610653804 A CN 201610653804A CN 106344564 A CN106344564 A CN 106344564A
- Authority
- CN
- China
- Prior art keywords
- indole
- alkoxyl
- application
- hydrogen
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC**(C(C)[N+](C)(C)**)*(C)(*)C[Rh] Chemical compound CC**(C(C)[N+](C)(C)**)*(C)(*)C[Rh] 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
Abstract
The invention provides an application of indole-3-carbinol and diindolylmethane and derivatives thereof in preparation of medicines for treating hair follicle keratosis. The medicines of the type can enhance ability of initiatively scavenging free radicals for cells by improving expression of specific genes in the cells, which resist the free radicals, and then reduce injury of the free radicals to the cells and tissue. Simultaneously, the used small molecule medicines are easy to obtain, low in cost, stable in quality, and convenient to save and transport, and have a wide application prospect.
Description
Technical field
The invention belongs to biomedicine technical field is and in particular to Indole-3-carbinol, di-indole methyl hydride and its derivant exist
Application in preparation treatment follicular keratosis disease drug.
Background technology
Follicular keratosis are a kind of chronic follicular keratosis diseases, the skin typically stretching side in extremity occur sand paper sample coarse or
Corium Gallus domesticuss sample outward appearance it is seen that scattered, syringe needle is big, pinnacle, pityriasis rubra pimple, there are horn plug, mostly normal skin tone or dark red in center
Color, general no conscious sympton, occasionally there is slight gargalesthesia.
Dyskeratosis follicularises are fairly common skin problems, and it is by a kind of autosomal inheritance disease of Gene Handling, has
50% chance entails the next generation, is autosomal dominant inherited disease, has family to be inclined to, also can because of thyroid dysfunction or
Caused by avitaminosis.Based on the pimple of normal color of the leather pityriasis rubra pinnacle, ash is arranged at pimple top for the skin lesion of keratosis pilaris
Color cutin thromboembolism.Sometimes visible fine hair is including center passes or curls, and peels off horn plug it is seen that small cupping, no
There is new horn plug to grow long again.Skin lesion does not merge, and is dispersed in distribution or gathering in groups, like " Corium Gallus domesticuss " outward appearance.
Dyskeratosis follicularises can allow people want except then fast, but squeezed, grab, being scratched with handss, the tissue edema around pore can be made,
So pore opening becomes less it is easier to block, and can produce acne, folliculitises；If scratched, inflammation and pigment more can be caused
Precipitation.So must not going to grab, going to scratch.So not only skin is easily injured, also can easily stimulate skin by hair follicle inflammation, make
Become cicatrix and pigementation.Painting carries out fruit acid and changes skin with retinoic acid or under specialist instructs, and can allow skin at several days
To improvement.But this is simply " emergent method ", curing the symptoms, not the disease, if often so processing, the barrier function of skin also can be made to become
Weaker, make skin drier, more sensitive..
Content of the invention
It is an object of the invention to provide a kind of disease symptom that can effectively reduce dyskeratosis follicularises, can be used as treatment hair
The molecule drug candidate of capsule seborrheic keratosis is Indole-3-carbinol, di-indole methyl hydride and its derivant in preparation treatment dyskeratosis follicularises
Application in medicine.
The present invention has the Indole-3-carbinol of structural formula (i) and its derivant in preparing follicular keratosis disease drug
Application, adjuvant is sodium alginate and carbamide, and in structural formula (i), r1, r2, r4, r5, r6, r7 are respectively h, halogenic substituent, sulphur
Acidic group or the nitrogenous alkoxyl of c1-c10 or c1-c10 alkoxyl or c1-c10 alkyl.
Preferably, in described structural formula (i), when r1, r2, r4, r5, r6, r7 are hydrogen, the chemical combination shown in this structural formula
Thing is Indole-3-carbinol；
When r5 be halogenic substituent, sulfonic group or the nitrogenous alkoxyl of c1-c10 or c1-c10 alkoxyl or c1-c10 alkyl, r1,
R2, r4, r6, r7 are hydrogen；
When r1 be halogenic substituent, sulfonic group or the nitrogenous alkoxyl of c1-c10 or c1-c10 alkoxyl or c1-c10 alkyl, r2,
R4, r5, r6, r7 are hydrogen；
When r2 be halogenic substituent, sulfonic group or the nitrogenous alkoxyl of c1-c10 or c1-c10 alkoxyl or c1-c10 alkyl, r1,
R4, r5, r6, r7 are hydrogen；
The present invention has the di-indole methyl hydride of structural formula (ii) and its derivant in preparing treating organs transplant rejection medicine
Application, adjuvant is sodium alginate and carbamide,
Wherein, r1, r2, r4, r5, r6, r7, r1 ', r2 ', r4 ', r5 ', r6 ', r7 ' are respectively hydrogen or halogen substituent group, sulfonic group
Or the nitrogenous alkoxyl of c1-c10 or c1-c10 alkoxyl or c1-c10 alkyl.
Preferably, in described structural formula (ii), as r1, r2, r4, r5, r6, r7, r1 ', r2 ', r4 ', r5 ', r6 ', r7 '
When being hydrogen, now the compound shown in this structural formula is di-indole methyl hydride；
When r5 and r5 ' is halogenic substituent, sulfonic group or the nitrogenous alkoxyl of c1-c10 or c1-c10 alkoxyl or c1-c10 simultaneously
Alkyl, r1, r2, r4, r6, r7, r1 ', r2 ', r4 ', r6 ', r7 ' be hydrogen.
When r1 and r1 ' is halogenic substituent, sulfonic group or the nitrogenous alkoxyl of c1-c10 or c1-c10 alkoxyl or c1- simultaneously
C10 alkyl, r2, r4, r5, r6, r7, r2 ', r4 ', r5 ', r6 ', r7 ' be hydrogen
When r2 and r2 ' is halogenic substituent, sulfonic group or the nitrogenous alkoxyl of c1-c10 or c1-c10 alkoxyl or c1-c10 simultaneously
Alkyl, r1, r4, r5, r6, r7, r1 ', r4 ', r5 ', r6 ', r7 ' be hydrogen.
The Indole-3-carbinol of the present invention, di-indole methyl hydride and its derivant are in preparation treatment follicular keratosis disease drug
Application, a kind of use of single compound Indole-3-carbinol or di-indole methyl hydride or derivatives thereof can treat hair follicle angle
Change disease, then obviously, the various forms of mixtures of above-claimed cpd also can reach certain therapeutic effect.
The substitutive derivative synthesizing i3c using commercially available substituted indoles possibly obtains these compounds
Easily method.The derivant of dim again may be by the method preparation of formaldehyde condensation substituted indoles.However, the latter's is bad
Gesture is that by-product is formed such that the dim derivant required for isolating and purifying is increasingly complex.
Using the Indole-3-carbinol (i3c) of the present invention, di-indole methyl hydride (dim) and its derivant, pharmaceutically may be used with multiple
Combined with the carrier accepting, by such as oral cavity, vein, nasal cavity, rectum or other any activity that can convey effective dose
The administering mode of material, can be prepared into various liquid preparations such as injection, oral liquid formulations etc. various has it is also possible to be prepared into
Imitate and be easy to the solid preparation such as capsule, suppository etc. being administered.Wherein, for injection or liquid preparation for oral use, needed for it
Carrier can be sterilized water, Sterile Saline or water solublity organic carrier such as cyclodextrin, Semen Maydis oil, olive oil, Oleic acid second
The medically acceptable carrier such as ester, glycolss；Solid dosage formulation can add the conventional adjuvant of solid preparation such as in preparation
Excipient glucose, Lactose, cellulose etc., also can add lubricant Polyethylene Glycol, magnesium stearate etc., and binding agent, taste masking
Adjunct ingredient needed for the solid preparations such as agent, then by operation molding such as mixing, granulations.Active matter in these preparations above-mentioned
The effective dose of matter is the amount that rejection symptom can be made substantially to reduce, and the research worker with routine techniquess is possible to determine this
The there is provided maximally effective dosage of reagent is provided and the time considers administering mode, drug metabolism, and some other medicine
For kinetic parameter such as drug distribution, clearance rate etc..
The present invention proposes Indole-3-carbinol, di-indole methyl hydride and its derivative compound in preparation treatment dyskeratosis follicularises
New application in medicine, this medicine can strengthen cell actively by improving the expression of the specific gene of intracellular free radical resisting
Remove the ability of free radical, mitigate the injury to cell and tissue for the free radical, rejection can be played and stop effect.Meanwhile,
Small-molecule drug used in the present invention is easily obtained, cheap, and stable in properties is easy to storage and transport, has wide
Application prospect.
Specific embodiment
With reference to embodiment, the present invention is described further:
Embodiment 1
(5- chloro-indole -3- methanol and 5, the preparation of 5 '-dichloro di-indole methyl hydride)
0.86ml phosphoryl chloride phosphorus oxychloride is slowly added into 2.9ml pre-cool to 0 DEG C of dimethylformamide.By 8.6mmol 5-
Chloro-indole (being purchased from Nanjing R＆M Fine Chemical Co., Ltd.) is dissolved in the dimethylformamide of 1.0ml, is then slowly added into
In the phosphinylidyne solutions of chlorine of aforementioned pre-cooling, the suspension being formed heats 60 minutes at 37 DEG C, until the yellow solution of clarification becomes
Flaxen pasty mass.Then add the frozen water of 1ml in this pasty mass, be slow added into 10ml and contain 3.75 grams of koh
Aqueous solution.Cool down after this mixture is heated to boiling, filter, washing, air drying can obtain 5- chloro-indole -3-
Acetaldehyde.
1.0 grams of 5- chloro-indole -3- acetaldehyde are dissolved in 5.0ml methanol, are continuously added into solid sodium borohydride, until excessive.So
Add 50ml water in backward reactant, be cooled to 0 DEG C, filter, lucifuge vacuum drying obtains 5- chloro-indole -3- methanol, yield
About 90%.
1.0 grams of 5- chloro-indole -3- methanol are added in the phosphate buffer that ph is 5.5, are stirred at room temperature 6 hours, reaction
Process is monitored by thin layer chromatography (tlc).Product filters, and lucifuge vacuum drying obtains 5,5 '-dichloro two indole
Methane, yield about 85%.
Embodiment 2
(5- nitroindoline -3- methanol and 5, the preparation of 5 '-dinitro di-indole methyl hydride)
5- nitroindoline can be by commercially available acquisition (Nanjing R＆M Fine Chemical Co., Ltd.).By 0.92ml phosphoryl chloride phosphorus oxychloride
It is slowly added into 2.9ml to pre-cool to 0 DEG C of dimethylformamide.8.2mmol 5- nitroindoline is dissolved in 1.0ml
Dimethylformamide in, be then slowly added in the phosphinylidyne solutions of chlorine of aforementioned pre-cooling, the suspension being formed 42 DEG C heat
90 minutes, until the yellow solution of clarification becomes flaxen pasty mass.Then add the ice of 1ml in this pasty mass
Water, is slow added into the aqueous solution that 10ml contains 3.75 grams of koh.Cool down after this mixture is heated to boiling, filter, washing,
Air drying can obtain 5- nitroindoline -3- acetaldehyde.
1.0 grams of 5- nitroindoline -3- acetaldehyde are dissolved in 5.0ml methanol, are continuously added into solid sodium borohydride, until excessive.
Then add 50ml water in reactant, be cooled to 0 DEG C, filter, lucifuge vacuum drying obtains 5- nitroindoline -3- methanol,
Yield about 87%.
1.0 grams of 5- nitroindoline -3- methanol are added in the phosphate buffer that ph is 5.5, are stirred at room temperature 6 hours, instead
Answer process to pass through thin layer chromatography (tlc) to be monitored.Product filters, and lucifuge vacuum drying obtains 5, and 5 '-dinitro is double
Indole methyl hydride, yield about 80%.
Embodiment 3
(5- amyl group Indole-3-carbinol and 5, the preparation of 5 '-diamyl-di-indole methyl hydride)
5- amyl group indole can be by commercially available acquisition (Nanjing R＆M Fine Chemical Co., Ltd.).By 0.82ml phosphoryl chloride phosphorus oxychloride
It is slowly added into 2.9ml to pre-cool to 0 DEG C of dimethylformamide.9.2mmol 5- amyl group indole is dissolved in 1.0ml
Dimethylformamide in, be then slowly added in the phosphinylidyne solutions of chlorine of aforementioned pre-cooling, the suspension being formed 37 DEG C heat
40-60 minute, until the yellow solution of clarification becomes flaxen pasty mass.Then add 1ml's in this pasty mass
Frozen water, is slow added into the aqueous solution that 10ml contains 3.75 grams of koh.Cool down after this mixture is heated to boiling, filter, water
Wash, air drying can obtain 5- amyl group indole -3- acetaldehyde.
1.0 grams of 5- amyl group indole -3- acetaldehyde are dissolved in 5.0ml methanol, are continuously added into solid sodium borohydride, until excessive.
Then add 50ml water in reactant, be cooled to 0 DEG C, filter, lucifuge vacuum drying obtains 5- amyl group Indole-3-carbinol,
Yield about 85%.
1.0 grams of 5- amyl group Indole-3-carbinols are added in the phosphate buffer that ph is 5.5, are stirred at room temperature 10 hours, instead
Answer process to pass through thin layer chromatography (tlc) to be monitored.Product filters, and lucifuge vacuum drying obtains 5, and 5 '-diamyl is double
Indole methyl hydride, yield about 70%.
Embodiment 4
(n- methoxy-Indole -3- methanol and n, the preparation of n '-dimethoxy-di-indole methyl hydride)
N- methoxy-Indole can be by commercially available acquisition (Nanjing R＆M Fine Chemical Co., Ltd.).By 0.86ml phosphinylidyne
Chlorine is slowly added into 2.9ml and pre-cools to 0 DEG C of dimethylformamide.8.9mmol n- methoxy-Indole is dissolved in
In the dimethylformamide of 1.0ml, it is then slowly added in the phosphinylidyne solutions of chlorine of aforementioned pre-cooling, the suspension being formed is 40
DEG C heating 60-90 minute, until clarification yellow solution become flaxen pasty mass.Then add in this pasty mass
Enter the frozen water of 1ml, be slow added into the aqueous solution that 10ml contains 3.75 grams of koh.Cool down after this mixture is heated to boiling,
Filter, washing, air drying can obtain n- methoxy-Indole -3- acetaldehyde.
1.0 grams of n- methoxy-Indole -3- acetaldehyde are dissolved in 5.0ml methanol, are continuously added into solid sodium borohydride, until mistake
Amount.Then add 50ml water in reactant, be cooled to 0 DEG C, filter, lucifuge vacuum drying obtains n- methoxy-Indole -3-
Methanol, yield about 80%.
1.0 grams of n- methoxy-Indole -3- methanol are added in the phosphate buffer that ph is 5.5, are stirred at room temperature 12 hours,
Course of reaction is monitored by thin layer chromatography (tlc).Product filters, and lucifuge vacuum drying obtains n, n '-dimethoxy
Base bis (indolyl) methane, yield about 70%.
Embodiment 5
(1- butyl -2 methyl indole -3- methanol and 1,1 '-dibutyl -2, the preparation of 2 '-dimethyl di-indole methyl hydride)
1- butyl -2 methyl indole can be by commercially available acquisition (Nanjing R＆M Fine Chemical Co., Ltd.).By 0.82ml
Phosphoryl chloride phosphorus oxychloride is slowly added into 2.9ml and pre-cools to 0 DEG C of dimethylformamide.By 8.2mmol 1- butyl -2- methyl Yin
Diindyl is dissolved in the dimethylformamide of 1.0ml, is then slowly added in the phosphinylidyne solutions of chlorine of aforementioned pre-cooling, and formed is outstanding
Supernatant liquid heats 90 minutes at 42 DEG C, until the yellow solution of clarification becomes flaxen pasty mass.Then to this pasty mass
The frozen water of middle addition 1ml, is slow added into the aqueous solution that 10ml contains 3.8 grams of koh.It is cold after this mixture is heated to boiling
But, filter, washing, air drying can obtain 1- butyl -2 methyl indole -3- acetaldehyde.
1.0 grams of 1- butyl -2 methyl indole -3- acetaldehyde is dissolved in 5.0ml methanol, is continuously added into solid sodium borohydride, directly
To excess.Then add 50ml water in reactant, be cooled to 0 DEG C, filter, lucifuge vacuum drying obtains 1- butyl -2- methyl
Indole-3-carbinol, yield about 85%.
1.0 grams of 1- butyl -2 methyl indole -3- methanol is added in the phosphate buffer that ph is 5.5, is stirred at room temperature 6
Hour, course of reaction is monitored by thin layer chromatography (tlc).Product filter, lucifuge vacuum drying i.e. obtain 1,1 '-
Dibutyl -2,2 '-dimethyl bis (indolyl) methane, yield about 80%.
Embodiment 6
(4- bromo indole -3- methanol and 4, the preparation of 4 '-dibromo di-indole methyl hydride)
0.86ml phosphoryl chloride phosphorus oxychloride is slowly added into 2.9ml pre-cool to 0 DEG C of dimethylformamide.By 8.6mmol 4-
Bromo indole (being purchased from Nanjing R＆M Fine Chemical Co., Ltd.) is dissolved in the dimethylformamide of 1.0ml, is then slowly added into
In the phosphinylidyne solutions of chlorine of aforementioned pre-cooling, the suspension being formed heats 60 minutes at 37 DEG C, until the yellow solution of clarification becomes
Flaxen pasty mass.Then add the frozen water of 1ml in this pasty mass, be slow added into 10ml and contain 3.75 grams of koh
Aqueous solution.Cool down after this mixture is heated to boiling, filter, washing, air drying can obtain 4- bromo indole -3-
Acetaldehyde.
1.0 grams of 4- bromo indole -3- acetaldehyde are dissolved in 5.0ml methanol, are continuously added into solid sodium borohydride, until excessive.So
Add 50ml water in backward reactant, be cooled to 0 DEG C, filter, lucifuge vacuum drying obtains 4- bromo indole -3- methanol, yield
About 90%.
1.0 grams of 4- bromo indole -3- methanol are added in the phosphate buffer that ph is 5.5, are stirred at room temperature 6 hours, reaction
Process is monitored by thin layer chromatography (tlc).Product filters, and lucifuge vacuum drying obtains 4,4 '-dibromo two indole
Methane, yield about 85%.
Zoopery
Material
Respectively the product Semen Maydis oil dissolving of embodiment 1- embodiment 6 is made into the oral liquid storage of 5.0mg/ml standby.
Experimental technique
By 4 months old rats 130 of health male 200～250g weight, it is divided into 13 groups every group 10, is randomly divided into model control group
And use the treatment group of the product treatment of embodiment 1- embodiment 6 respectively.
Mice is used for testing first 1 day in abdominal part unhairing, area about 3cm2, and experimental day and next day apply in unhairing position
Cloth 0.5%dnfb (dnfb with 4:1 acetone olive oil for substrate configure) each sensitization of 25 μ l once, after sensitization the 5th day in mice
Abdominal part applies 0.5% dnfb20 μ l induction.Rat is fixed, fully exposes the visual field, survey a dyskeratosis follicularises area within every 7 days
Until the 4th week.
Measured area is as follows
| Start | First week | Second week | 3rd week | 4th week | |
| Control sample | 100% | 100% | 100% | 100% | 100% |
| Embodiment 1 | 100% | 90% | 80% | 64% | 30% |
| Embodiment 2 | 100% | 91% | 82% | 70% | 35% |
| Embodiment 3 | 100% | 93% | 85% | 68% | 40% |
| Embodiment 4 | 100% | 93% | 86% | 70% | 41% |
| Embodiment 5 | 100% | 94% | 86% | 71% | 41% |
| Embodiment 6 | 100% | 92% | 83% | 66% | 33% |
By embodiment group and the matched group contrast clinical trial surface of 4 weeks, product of the present invention has in treatment dyskeratosis follicularises
Significant curative effect, can reduce dyskeratosis follicularises area.Therefore, Indole-3-carbinol, di-indole methyl hydride and its derivative compound are in system
New application in standby treatment follicular keratosis disease drug.
The foregoing is only one embodiment of the invention, be not intended to limit the present invention, all employing equivalents or equivalent transformation
The technical scheme that obtained of mode, all fall within protection scope of the present invention.
Claims (10)
1. there is the application in preparing follicular keratosis disease drug of the Indole-3-carbinol and its derivant of structural formula (i), adjuvant is
Sodium alginate and carbamide, in structural formula (i), r1, r2, r4, r5, r6, r7 are respectively h, halogenic substituent, sulfonic group or c1-c10
Nitrogenous alkoxyl or c1-c10 alkoxyl or c1-c10 alkyl.
2. according to claim 1 application it is characterised in that: in described structural formula (i), as r1, r2, r4, r5, r6, r7
When being hydrogen, the compound shown in this structural formula is Indole-3-carbinol.
3. application according to claim 2 it is characterised in that: r5 is halogenic substituent, sulfonic group or c1-c10 contain azane
Epoxide or c1-c10 alkoxyl or c1-c10 alkyl, r1, r2, r4, r6, r7 are hydrogen.
4. application according to claim 2 it is characterised in that: r1 is halogenic substituent, sulfonic group or c1-c10 contain azane
Epoxide or c1-c10 alkoxyl or c1-c10 alkyl, r2, r4, r5, r6, r7 are hydrogen.
5. according to claim 2 application it is characterised in that: when r2 be halogenic substituent, sulfonic group or c1-c10 nitrogenous
Alkoxyl or c1-c10 alkoxyl or c1-c10 alkyl, r1, r4, r5, r6, r7 are hydrogen.
6. the present invention there is the di-indole methyl hydride of structural formula (ii) and its derivant is preparing treating organs transplant rejection medicine
In application, adjuvant is sodium alginate and carbamide.
7. according to claim 6 application it is characterised in that: r1, r2, r4, r5, r6, r7, r1 ', r2 ', r4 ', r5 ',
R6 ', r7 ' are respectively hydrogen or halogen substituent group, sulfonic group or the nitrogenous alkoxyl of c1-c10 or c1-c10 alkoxyl or c1-c10 alkane
Base.
8. according to claim 6 application it is characterised in that: in described structural formula (ii), when r1, r2, r4, r5, r6,
R7, r1 ', r2 ', r4 ', r5 ', r6 ', r7 ' be when being hydrogen, now the compound shown in this structural formula is di-indole methyl hydride.
9. according to claim 6 application it is characterised in that: when r5 and r5 ' simultaneously be halogenic substituent, sulfonic group or
The nitrogenous alkoxyl of c1-c10 or c1-c10 alkoxyl or c1-c10 alkyl, r1, r2, r4, r6, r7, r1 ', r2 ', r4 ', r6 ',
R7 ' is hydrogen.
10. according to claim 6 application it is characterised in that: when r1 and r1 ' simultaneously be halogenic substituent, sulfonic group or
The nitrogenous alkoxyl of c1-c10 or c1-c10 alkoxyl or c1-c10 alkyl, r2, r4, r5, r6, r7, r2 ', r4 ', r5 ', r6 ',
R7 ' is hydrogen；: when r2 and r2 ' be simultaneously halogenic substituent, sulfonic group or the nitrogenous alkoxyl of c1-c10 or c1-c10 alkoxyl or
C1-c10 alkyl, r1, r4, r5, r6, r7, r1 ', r4 ', r5 ', r6 ', r7 ' be hydrogen.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610653804.0A CN106344564A (en) | 2016-08-11 | 2016-08-11 | Application of indole-3-carbinol and diindolylmethane and derivatives thereof in preparation of medicines for treating hair follicle keratosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610653804.0A CN106344564A (en) | 2016-08-11 | 2016-08-11 | Application of indole-3-carbinol and diindolylmethane and derivatives thereof in preparation of medicines for treating hair follicle keratosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106344564A true CN106344564A (en) | 2017-01-25 |
Family
ID=57843810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610653804.0A Pending CN106344564A (en) | 2016-08-11 | 2016-08-11 | Application of indole-3-carbinol and diindolylmethane and derivatives thereof in preparation of medicines for treating hair follicle keratosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106344564A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105012297A (en) * | 2015-06-24 | 2015-11-04 | 安徽四正医药科技有限公司 | Use of indole-3-carbinol, bis-indolymethane and derivatives thereof in drugs for treatment on contact dermatitis |
| CN105343450A (en) * | 2015-10-28 | 2016-02-24 | 皖南医学院 | Emulsion for treating keratosis pilaris and preparation method of emulsion |
-
2016
- 2016-08-11 CN CN201610653804.0A patent/CN106344564A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105012297A (en) * | 2015-06-24 | 2015-11-04 | 安徽四正医药科技有限公司 | Use of indole-3-carbinol, bis-indolymethane and derivatives thereof in drugs for treatment on contact dermatitis |
| CN105343450A (en) * | 2015-10-28 | 2016-02-24 | 皖南医学院 | Emulsion for treating keratosis pilaris and preparation method of emulsion |
Non-Patent Citations (1)
| Title |
|---|
| 张笑铭: "毛囊角化病的诊断与治疗", 《黑龙江中医药》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106349148B (en) | New indole class compound with anti-tumor metastasis and anti-inflammatory activity, synthesis and application | |
| CN102869258A (en) | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose) polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency | |
| CN105523955B (en) | Compound and its purposes in medicine preparation | |
| CN102389419A (en) | Application of indole-3-carbinol, diindolylmethane and derivatives thereof to preparation of medicine for preventing and controlling atherosclerosis | |
| Wu et al. | Regulating the bacterial oxygen microenvironment via a perfluorocarbon-conjugated bacteriochlorin for enhanced photodynamic antibacterial efficacy | |
| CN113461697A (en) | Chlorin compound and preparation method and application thereof | |
| CN103040864B (en) | Medical application of selenium phosphate compound | |
| CN101766779B (en) | Compound medicine for vitligo treatment and preparation method thereof | |
| CN107970432B (en) | Tumor cell abnormal lipid metabolism inhibitor containing plant cyclic peptide as effective component and application thereof | |
| CN106924732A (en) | A kind of ultrasonic therapy cancer target type haematoporphyrin injection and preparation method thereof | |
| CN103143013B (en) | Photosensitive medicinal preparation containing amino poly-carboxylic acid modification tetraphenylporphyrin compound and purpose thereof | |
| CN106344564A (en) | Application of indole-3-carbinol and diindolylmethane and derivatives thereof in preparation of medicines for treating hair follicle keratosis | |
| CN108721618B (en) | Fe3O4@ CuO @ OxyHb @ ZnPc @ m-HA five-element composite system and preparation method and application thereof | |
| CN102429901B (en) | Application of indole-3-carbinol, diindolylmethane and derivatives thereof in preparation of medicaments for preventing and treating renal fibrosis | |
| CN106265644A (en) | The application in preparation treatment seborrheic alopecia medicine of indole 3 methanol, di-indole methyl hydride and derivant thereof | |
| CN101703503B (en) | Application of organic dicarboxylic acid salts in preparing medicaments for preventing and treating cataract | |
| CN103690535A (en) | Application of demethyleneberberine hydrochloride in preparation of medicament for preventing and/or treating hepatic fibrosis | |
| CN102335169B (en) | Application of indole-3-carbinol, diindolyl methane and derivatives thereof in preparation of medicaments for treating senile dementia | |
| CN106565718A (en) | Selenium-containing compound and use thereof | |
| CN105434432B (en) | N-Hydroxyphthalimide class compound application in preparation of anti-tumor drugs | |
| CN106265643A (en) | The application in preparation treatment prostate hyperplasia medicine of indole 3 methanol, di-indole methyl hydride and derivant thereof | |
| CN104997772A (en) | Application of indole-3-methanol, diindolylmethane and derivatives thereof in drugs used for treating psoriasis | |
| CN106344563A (en) | Application of indole-3-carbinol and diindolylmethane and derivatives thereof in preparation of medicines for treating lupus erythematosus | |
| CN108904510A (en) | Dexamethasone is used to inhibit or treat the purposes of cancer of pancreas | |
| CN104887790B (en) | Treat herbal mixture water extract of acute pancreatitis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170125 |
|
| WD01 | Invention patent application deemed withdrawn after publication |